Language:

Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications

Internal Medicine, 2019/06/15, Vol.58(12), pp.1665-1672 [Peer Reviewed Journal]

2019 by The Japanese Society of Internal Medicine ;Copyright Japan Science and Technology Agency 2019 ;Copyright © 2019 by The Japanese Society of Internal Medicine ;ISSN: 0918-2918 ;EISSN: 1349-7235 ;DOI: 10.2169/internalmedicine.2489-18 ;PMID: 30799370

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications
Author: Ikeda, Ken ; Ebina, Junya ; Kawabe, Kiyokazu ; Iwasaki, Yasuo
Subjects: anti-PD medication ; Audit committees ; Biomarkers ; Differential diagnosis ; Dopamine ; Dopamine receptors ; Dopamine transporter ; dopamine transporter imaging ; Longitudinal studies ; Medical imaging ; Movement disorders ; Neostriatum ; Neurodegenerative diseases ; Neurological diseases ; Neurons ; Parkinson disease ; Parkinson's disease ; Parkinsons disease ; progressive change ; Review ; Synaptic cleft ; Therapeutic applications ; therapeutic modification ; Transport buildings, stations and terminals ; Tremor
Is Part Of: Internal Medicine, 2019/06/15, Vol.58(12), pp.1665-1672
Description: Parkinson disease (PD) is a slowly progressive neurodegenerative disease characterized by the loss of dopaminergic neurons and terminals in the nigrostriatal system. Dopamine transporter (DAT) imaging is widely performed for the differential diagnosis of PD and other degenerative parkinsonism from essential tremor, vascular parkinsonism, and drug-induced parkinsonism. DAT is the plasma membrane carrier specific to dopamine neurons that are responsible for re-uptaking dopamine from the synaptic cleft back into the nerve ending. DAT binding might reflect striatal presynaptic dysfunction or DAT expression in PD patients. Longitudinal studies of DAT imaging have reported progressive changes from early PD patients. This imaging may be used as a progressive biomarker. Follow-up DAT imaging for therapeutic interventions has been applied for several anti-parkinsonian drugs. We herein review the progressive changes and therapeutic modification of DAT binding by anti-PD medications in early PD patients.
Publisher: Japan: The Japanese Society of Internal Medicine
Language: English
Identifier: ISSN: 0918-2918
EISSN: 1349-7235
DOI: 10.2169/internalmedicine.2489-18
PMID: 30799370
Source: PubMed Central
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications

2019 by The Japanese Society of Internal Medicine ;Copyright Japan Science and Technology Agency 2019 ;Copyright © 2019 by The Japanese Society of Internal Medicine ;ISSN: 0918-2918 ;EISSN: 1349-7235 ;DOI: 10.2169/internalmedicine.2489-18 ;PMID: 30799370

Searching Remote Databases, Please Wait